03.08.2022, Author: Nico Popp

Stock news: AccuTOX™ - New project from Defence Therapeutics against cancer cells — CEO: "Positive effects on entire product pipeline."

  • Biotechnology

Vaccinations against various types of cancer and drug boosters that are suitable for reducing the effective doses of drugs - this is what Defence Therapeutics stood for, until yesterday. Now the Company has expanded its portfolio: the active ingredient AccuTOX™ ensures that cancer cells die. A Phase 1 trial is planned for 2023. Find out what the new application means and how the Company is otherwise positioned in our update.

Time to read: 3 minutes

The biotech company Defence Therapeutics recently announced the discovery of a new DNA-damaging function of the active ingredient AccuTOX™. According to the report, the active ingredient causes cancer cells to die. Cancer is considered a condition of uncontrolled growth of malignant cells. Malignant cells have lost the ability to initiate their own cell death. AccuTOX™ remedies exactly this situation, according to Defence Therapeutics.

Preliminary work on Phase 1 trials currently underway

"AccuTOX™ impairs several critical signaling pathways, including DNA replication, cell division, nuclear integrity and several modifications that affect DNA activity. The accumulation of exhaustive cell repair mechanisms triggered by AccuTOX™, combined with the build-up of misfolded proteins and generation of free radicals, induces irreversible DNA damage, leading to a general collapse in several cellular pathways resulting in effective cancer cell death", summarizes the Company on the mode of action.

It was already known that AccuTOX works. The new findings go much further. Source: Defence Therapeutics old: Defence Therapeutics

The newly discovered function of AccuTOX™ had previously only been discussed as a possible application. Defence Therapeutics is currently conducting so-called GLP studies with AccuTOX™ to initiate a Phase 1 study in North America. GLP stands for "Good Laboratory Practice" and includes standardized procedures to ensure the quality of data collected during studies. Phase 1 studies aim to determine the safety of active substances. Among other things, they investigate how high doses of active ingredients can be used without endangering patient safety.

AccuTOX™ with positive effects on the entire product pipeline

In addition to the Phase 1 trial around AccuTOX™, the Company is also planning studies around its immuno-oncology activities. Specifically, this involves vaccine candidates against skin and cervical cancer. Thus, Defence Therapeutics has several promising projects. Central behind all the Company's activities is its patented Accum™ technology. Specifically, this is a platform approach that can effectively deliver antibody-drug conjugates (ADCs) into cells. This is expected to increase the efficacy of drugs. Since Accum™ can be administered with both existing compounds and Defence Therapeutics' proprietary developments, the 100% proprietary research-based technology is the basis for several potential revenue streams for Defence Therapeutics. The recent discovery adds another exciting project to the Company's portfolio.

"Defence's breakthrough discovery with its AccuTOX formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with Accum™. Discovering that AccuTOX™ can behave as a chemotherapeutic agent that targets cancer cell DNA and as a booster for immune-checkpoint inhibitors is a new discovery that is very valuable to Defence's pipeline and future potential developments. The AccuTOX™ represents a novel technology as a platform for targeting multiple cancer types. This new discovery creates significant value and applications for our antibody-drug conjugate (ADCs) pipeline. The results show that AccuTOX™ is the perfect-potent small molecule for the development of our proprietary ADC", said Sébastien Plouffe, CEO of Defence Therapeutics.

Defence Therapeutics
AccuTOX as an optimal complement to Defence Therapeutics' technology: CEO Sébastien Plouffe source: Defence Therapeutics

Three hot irons in the fire - analyst study increases visibility

With the expansion of its technology portfolio and the ongoing GLP study ahead of Phase 1 trials starting in 2023, Defence Therapeutics is on several paths to market. In order to be able to implement all projects, the Company will need additional capital for the foreseeable future. Just a few weeks ago, a comprehensive research study by Canaccord Genuity provided a comprehensive overview of the investment story and likely increased the visibility of the Company.

The update is to our initial Report 12/21.

Conflict of interest

Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

For this reason, there is a concrete conflict of interest.

The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

Risk notice

Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.